New report confirms Smith+Nephew’s OXINIUM™ Technology is the best performing bearing surface at 20 years for total hip arthroplasty

Core Insights - Smith+Nephew's OXINIUM technology demonstrates the highest survivorship rate of 94.1% for total hip arthroplasty over a 20-year period, as reported by the Australian Orthopaedic Association National Joint Replacement Registry [1] - The performance of OXINIUM in combination with highly cross-linked polyethylene (XLPE) has been corroborated by multiple registries, indicating a significant reduction in the need for revision surgeries [2][3] - OXINIUM/XLPE implants show a 35% lower risk of revision at 10 years compared to other modular acetabular implants, highlighting their reliability for long-term outcomes [3] Performance Data - The AOANJRR report indicates that bearing wear, previously a leading cause of hip replacement failure, has been virtually eliminated with the use of OXINIUM on XLPE [3] - OXINIUM's unique manufacturing process results in a ceramicised metal that offers superior durability, wear resistance, and corrosion resistance compared to traditional materials [4] - The differentiated composition of OXINIUM includes virtually no nickel, cobalt, or chromium, leading to a 30x reduction in pro-inflammatory markers [4] Market Position - Smith+Nephew generated annual sales of $5.8 billion in 2024 and operates in around 100 countries, positioning itself as a significant player in the global medical technology market [8] - The company focuses on the repair, regeneration, and replacement of soft and hard tissue, aiming to enhance patients' quality of life through innovative technologies [7]